- Home
- EU vs EYPT Comparison
EU vs EYPT Comparison
Compare EU & EYPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | EU | EYPT |
|---|---|---|
| Founded | 2009 | 1987 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Metals and Minerals | Biotechnology: Laboratory Analytical Instruments |
| Sector | Basic Materials | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 464.5M | 1.5B |
| IPO Year | N/A | 2005 |
Fundamental Metrics
Financial Performance| Metric | EU | EYPT |
|---|---|---|
| Price | $3.27 | $15.40 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | $4.00 | ★ $28.75 |
| AVG Volume (30 Days) | ★ 2.9M | 912.6K |
| Earning Date | 03-02-2026 | 03-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $44,142,000.00 | $42,339,000.00 |
| Revenue This Year | $17.41 | N/A |
| Revenue Next Year | $95.45 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.01 | $3.91 |
| 52 Week High | $4.19 | $19.11 |
Technical Indicators
Market Signals| Indicator | EU | EYPT |
|---|---|---|
| Relative Strength Index (RSI) | 67.78 | 42.97 |
| Support Level | $3.06 | $14.50 |
| Resistance Level | $3.48 | $17.61 |
| Average True Range (ATR) | 0.20 | 1.08 |
| MACD | 0.05 | -0.22 |
| Stochastic Oscillator | 75.53 | 24.73 |
Price Performance
Historical ComparisonAbout EU enCore Energy Corp.
enCore Energy Corp together with its subsidiary, is engaged in the acquisition and exploration of resource properties of uranium resource properties in the United States. The holds a portfolio of uranium assets located in New Mexico, South Dakota, Wyoming, Texas, Utah, Colorado, and Arizona in the USA, and is advancing its properties with a focus on utilizing in-situ recovery. The company's Projects are South Texas Operations, Dewey-Burdock Project, Gas Hills Project, Crownpoint & Hosta Butte Project, PFN (Prompt Fission Neutron) Technology, and Other Assets.
About EYPT EyePoint Pharmaceuticals Inc.
EyePoint Inc focuses on developing and commercializing innovative therapeutics for serious retinal diseases. It develops therapies for serious retinal diseases to provide durable treatments that may reduce the frequency of follow-up care. The company's pipeline program includes i) DURAVYU: a sustained release product candidate for retinal diseases with the potential to provide patients with improved visual outcomes with less burden. ii) EYP-2301: early-stage program using Durasert E technology to deliver razuprotafib, a TIE-2 agonist targeting VE-PTP for vascular stability in retinal diseases like wet AMD.